新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 干细胞&iPS » 武田与日本京都大学iPS细胞研究所(CiRA)达成10年干细胞合作

武田与日本京都大学iPS细胞研究所(CiRA)达成10年干细胞合作

来源:生物谷 2015-04-17 12:50

2015年4月17日讯 /生物谷BIOON/ --日本制药巨头武田(Takeda)近日宣布,与日本京都大学iPS细胞研究所(CiRA)达成了一项为期10年的iPS细胞研究合作,双方将联手开发诱导多能干细胞(iPSC)在多个领域的临床应用,如心脏衰竭、糖尿病、神经性疾病、肿瘤免疫治疗等。该项“武田-CiRA iPS细胞应用联合项目(T-CiRA)”旨在利用iPSC技术加速推进药物发现和细胞疗法的多个研究项目。CiRA所长山中伸弥(Shinya Yamanaka)将负责指导T-CiRA项目,武田将提供长期资金支持、科研管理建议以及提供位于日本藤泽湘南研究中心的设施。

诱导多能干细胞(iPSC)技术有望对未来的医学治疗带来突破性的变革,而且它们的应用涵盖多个领域,包括药物发现、细胞疗法、药物安全性评估等。在为期10年的合作中,武田和CiRA将在CiRA研究专家的领导下联合运营项目。此次合作有望为iPSC技术科学和应用向临床实践的推进做出显著贡献,而这需要大量的时间、精力和投资。

在为期10年的合作期,武田将为其湘南研究中心提供科研设施,提供200亿日元(约合1.38亿美元)的合作资金。同时,武田还将提供价值超过120亿日元(约合1.008亿美元)的研究支持(设施、设备、武田研究人员及各种研究服务);包括从全球招聘的新的研究人员在内大约100名研究人员将在武田的湘南研究中心从事共同研究。此外,武田还将为合作项目提供相关的研究资产,如武田的化合物文库。

潜在的初始研究项目将包括心脏衰竭、糖尿病、神经精神病学疾病、肿瘤免疫疗法。随着合作的推进,其他项目也将纳入进来。一旦运作起来,大约有10个项目将会同期开展。

日本京都大学iPS细胞研究所(CiRA)隶属于日本京都大学,是一个专注于干细胞研究的顶级科研机构,现任所长山中伸弥是2012年诺贝尔生理学或医学奖得主,是干细胞研究领域的泰山北斗级人物。(生物谷Bioon.com)

英文原文:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research

CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research

Kyoto and Osaka, Japan, April 17, 2015 – Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today that they will work together to develop clinical applications of induced pluripotent stem cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer immunotherapy. The “Takeda-CiRA Joint Program for iPS Cell Applications” (T-CiRA) is designed to expedite multiple research projects for drug discovery and cell therapy using iPS cells. CiRA Director Shinya Yamanaka, a Nobel laureate for his work on iPS cells, will direct the Program, while Takeda provides long-term funding, recommendations on research management, and facilities at its Shonan Research Center, Fujisawa, Japan.

iPS cell technologies have the potential to bring about ground-breaking transformations to future medical treatments, and their applications span a variety of fields, including drug discovery, cell therapy and drug safety assessments. During a period of 10 years, Takeda and CiRA will jointly run projects led by research experts invited from CiRA. The collaboration is expected to make significant contributions to the science and application of iPS cell technology into clinical practice, which requires a significant amount of time, effort and investment.

“This 10-year joint program with Takeda, Japan’s largest pharmaceutical company, will become a powerful engine to realizing medical applications using iPS cells,” said Yamanaka. “We sincerely thank Takeda’s commitment to iPS cell research. This partnership will contribute to the development of new therapies to cure not only major diseases but also rare ones.”

“I am excited that we will be able to collaborate with CiRA, the world’s leading institute dedicated to pioneering iPS cell research,” said Christophe Weber, President, and Chief Executive Officer of Takeda. “Through this partnership, our company will provide significant assistance over a long period to CiRA’s research into iPS cell technology applications, which is a vital part of Japan Revitalization Strategy. It is our hope to deliver innovative treatments that meet patient needs as soon as possible through this collaboration between Takeda and CiRA.”

This collaboration is aligned with the purpose of National Projects of Japan on clinical applications of iPS cell technologies. Takeda will provide research facilities at its Shonan Research Center and collaborative funding of 20 billion yen over a 10-year period. In addition, Takeda will provide more than 12 billion yen worth of research support (facility, equipment, Takeda researchers and various research services) over the 10-year collaboration period. About 100 researchers including new researchers recruited globally are to be based at Takeda’s Shonan Research Center engaged in joint research, with each contributing about 50 researchers. Also, the access to special research assets, such as Takeda's compound libraries, will be provided for the collaboration.

Potential initial research projects include heart failure, diabetes mellitus, neuro-psychiatric disorders, and cancer immunotherapy. Additional projects will be included as the collaboration moves forward. Once set up, around 10 projects will be pursued concurrently.

About the Center for iPS Cell Research and Application at Kyoto University (CiRA)
CiRA, the 14th research institute at Kyoto University, was established on April 1, 2010 to serve as the world’s first core institute dedicated to pioneering iPS cell research. With Dr. Shinya Yamanaka serving as Director, the Center’s 30 research groups are engaged in basic research, research leading to preclinical and clinical applications, and research of ethical issues, with the overall goal of using iPS cells to realize regenerative medicine and drug discovery. Additional information about CiRA is available through its website at www.cira.kyoto-u.ac.jp.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库